United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Nuvalent (NASDAQ: NUVL) to release topline ALKOVE-1 trial data for neladalkib in advanced ALK-positive NSCLC on November 17 Nuvalent will present pivotal data for neladalkib in ALK-positive NSCLC on Nov 17. See what investors and analysts are expecting from ALKOVE-1. bySrinathNovember 15, 2025